Champions Oncology, Inc. has returned to profitability in fiscal 2025, primarily driven by growth in its research services utilizing a proprietary TumorBank of approximately 1,500 PDX models. The company's integrated Datacenter and artificial intelligence-powered SaaS platform support both experimental and computational oncology research for pharmaceutical and biotech clients worldwide. Despite competitive pressures from well-resourced incumbents and open-source alternatives, Champions continues to invest in expanding its TumorBank, enhancing analytical platforms, and advancing novel drug discovery efforts in targeted therapy, immune oncology, and cell therapy. Operating cash flows have improved substantially, supporting a positive free cash flow profile as product offerings scale, though liquidity remains a key watch area going forward.